Lipid-based formulations (LBF) enhance oral drug absorption by promoting drug solubilization and supersaturation. The aim of the study was to determine the effect of the lipid carrier type, drop size and surfactant concentration on the rate of fenofibrate release in a bicarbonate-based in vitro digestion model. The effect of the lipid carrier was studied by preparing type I LBF with drop size ≈ 2 µm, based on medium-chain triglycerides (MCT), sunflower oil (SFO), coconut oil (CNO) and cocoa butter (CB). The drop size and surfactant concentration effects were assessed by studying MCT and SFO-based formulations with a drop size between 400 nm and 14 µm and surfactant concentrations of 1 or 10%. A filtration through a 200 nm filter followed by...
Lipid based formulations (LBF) provide well proven opportunities to enhance the oral absorption of d...
The majority of emerging drug candidates are not suited for conventional oral dosage forms, as they ...
The majority of emerging drug candidates are not suited for conventional oral dosage forms, as they ...
Purpose: To evaluate the role of supersaturation in the in vivo absorption of fenofibrate (FFB), aft...
The current studies sought to explore the impact of drug supersaturation and precipitation during th...
The LFCS Consortium was established to develop standardized <i>in vitro</i> tests for lipid-based fo...
Development of formulations containing poorly water-soluble drugs (PWSDS) incorporated in lipid-base...
The rising numbers of poorly water soluble drugs found in the pipelines of the pharmaceutical indust...
This thesis has explored the use of lipid-based formulations (LBF) to enhance the oral bioavailabili...
Development of formulations containing poorly water-soluble drugs (PWSDS) incorporated in lipid-base...
Background: The choice of lipid excipients and their origin are crucial determinant factors in the d...
Lipid based formulations (LBFs) are a promising formulation strategy for many poorly water-soluble d...
The scientific rationale for selection of the surfactant type during oral formulation development re...
The current project has explored the determinants of drug absorption following oral administration o...
The aim of this study is to investigate the potential of nanostructured lipid carriers (NLCs) in imp...
Lipid based formulations (LBF) provide well proven opportunities to enhance the oral absorption of d...
The majority of emerging drug candidates are not suited for conventional oral dosage forms, as they ...
The majority of emerging drug candidates are not suited for conventional oral dosage forms, as they ...
Purpose: To evaluate the role of supersaturation in the in vivo absorption of fenofibrate (FFB), aft...
The current studies sought to explore the impact of drug supersaturation and precipitation during th...
The LFCS Consortium was established to develop standardized <i>in vitro</i> tests for lipid-based fo...
Development of formulations containing poorly water-soluble drugs (PWSDS) incorporated in lipid-base...
The rising numbers of poorly water soluble drugs found in the pipelines of the pharmaceutical indust...
This thesis has explored the use of lipid-based formulations (LBF) to enhance the oral bioavailabili...
Development of formulations containing poorly water-soluble drugs (PWSDS) incorporated in lipid-base...
Background: The choice of lipid excipients and their origin are crucial determinant factors in the d...
Lipid based formulations (LBFs) are a promising formulation strategy for many poorly water-soluble d...
The scientific rationale for selection of the surfactant type during oral formulation development re...
The current project has explored the determinants of drug absorption following oral administration o...
The aim of this study is to investigate the potential of nanostructured lipid carriers (NLCs) in imp...
Lipid based formulations (LBF) provide well proven opportunities to enhance the oral absorption of d...
The majority of emerging drug candidates are not suited for conventional oral dosage forms, as they ...
The majority of emerging drug candidates are not suited for conventional oral dosage forms, as they ...